Allergy treatment never ends.
We’re working on something that does.
AbstimX: Two antibodies, working together to restore the off switch for allergic and other inflammatory diseases.
Reginald, age 6
The current standard of care is symptom management.
4,000 pills.
For a dog. Over a lifetime. To block symptoms.
Bi-weekly injections
For a person. Every year. Same disease.
Stop the treatment, and you are back where you started.
Most treatments suppress the system. Ours aims to restore it.
The immune system has the intelligence to turn off. In allergic disease, that ability is impaired.
AbstimX combines two antibodies that the body already makes, given as a finite course rather than continuously. The aim is to restore the upstream regulation instead of overriding it.
These antibodies have been around for decades.
Our patented approach has not.
Both come from our own human immune system, and both have been FDA approved for decades.
Nobody has put them together this way.
Where we are
Patent Estate
Granted in the US, China and Japan
Complete
Preclinical evidence
Six peer-reviewed publications, two species
Complete
Canine clinical pilot study
Underway at an independent academic centre
In progress
Product definition
Specification, manufacturing, cost
In progress
Human Studies
Not yet started
Not started